196 related articles for article (PubMed ID: 38036617)
1. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling.
Bell M; Lange S; Sejdiu BI; Ibanez J; Shi H; Sun X; Meng X; Nguyen P; Sutton M; Wagner J; Kc A; Langfitt D; Patil SL; Tan H; Pandey RV; Li Y; Yuan ZF; Anido AA; Ho M; Sheppard H; Vogel P; Yu J; Peng J; Chi H; Babu MM; Krenciute G; Gottschalk S
Nat Biomed Eng; 2024 Apr; 8(4):380-396. PubMed ID: 38036617
[TBL] [Abstract][Full Text] [Related]
2. Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells.
Yoshikawa T; Ito Y; Wu Z; Kasuya H; Nakashima T; Okamoto S; Amaishi Y; Zhang H; Li Y; Matsukawa T; Inoue S; Kagoya Y
Cell Rep Med; 2024 May; 5(5):101526. PubMed ID: 38670095
[TBL] [Abstract][Full Text] [Related]
3. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-23 engineering improves CAR T cell function in solid tumors.
Ma X; Shou P; Smith C; Chen Y; Du H; Sun C; Porterfield Kren N; Michaud D; Ahn S; Vincent B; Savoldo B; Pylayeva-Gupta Y; Zhang S; Dotti G; Xu Y
Nat Biotechnol; 2020 Apr; 38(4):448-459. PubMed ID: 32015548
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
6. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
7. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
8. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
9. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
10. Dynamics and non-canonical aspects of JAK/STAT signalling.
Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
[TBL] [Abstract][Full Text] [Related]
11. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT: Why choose a classical or an alternative pathway when you can have both?
Puigdevall L; Michiels C; Stewardson C; Dumoutier L
J Cell Mol Med; 2022 Apr; 26(7):1865-1875. PubMed ID: 35238133
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
14. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
15. Jaks and cytokine receptors--an intimate relationship.
Haan C; Kreis S; Margue C; Behrmann I
Biochem Pharmacol; 2006 Nov; 72(11):1538-46. PubMed ID: 16750817
[TBL] [Abstract][Full Text] [Related]
16. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
[TBL] [Abstract][Full Text] [Related]
17. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
19. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
Shum T; Omer B; Tashiro H; Kruse RL; Wagner DL; Parikh K; Yi Z; Sauer T; Liu D; Parihar R; Castillo P; Liu H; Brenner MK; Metelitsa LS; Gottschalk S; Rooney CM
Cancer Discov; 2017 Nov; 7(11):1238-1247. PubMed ID: 28830878
[TBL] [Abstract][Full Text] [Related]
20. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]